Search results
Showing 1 to 13 of 13 results for cg181
diagnosed for diagnosis as set out in CG127 and QRISK assessment as set out in CG181. After 12 months, there was an increase in 6,167...
Re-engineering the Post-Myocardial Infarction Medicines Optimisation Pathway
including lipid modification (CG181)
Recommendation ID CG181/4 Question What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with
Recommendation ID CG181/2 Question What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can
What is the effectiveness of statin therapy in older people?
Recommendation ID CG181/3 Question What is the effectiveness of statin therapy in older people? Any explanatory notes(if applicable)
Recommendation ID CG181/1 Question What is the effectiveness of age alone and other routinely available risk factors compared with the
Recommendation ID CG181/5 Question What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20
Innovative Medicines Optimisation Clinic for PCSK9 inhibitors & Statin Intolerance
including lipid modification (CG181)
Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)
This guideline has been updated and replaced by NICE guideline NG238.
Cardiovascular disease. Patient decision aid on should I take a statin?
risk assessment and reduction, including lipid modification. NICE guideline CG181 Evidence review C statins: efficacy and adverse...
This guidance has been updated and replaced by NICE guideline CG181.
This guidance has been updated and replaced by NICE guideline CG181.
CG181/1 | What is the effectiveness of age alone and other routinely available